[go: up one dir, main page]

IL185401A0 - Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes - Google Patents

Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes

Info

Publication number
IL185401A0
IL185401A0 IL185401A IL18540107A IL185401A0 IL 185401 A0 IL185401 A0 IL 185401A0 IL 185401 A IL185401 A IL 185401A IL 18540107 A IL18540107 A IL 18540107A IL 185401 A0 IL185401 A0 IL 185401A0
Authority
IL
Israel
Prior art keywords
rimonabant
medicaments
diabetes
prevention
preparation
Prior art date
Application number
IL185401A
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0501861A external-priority patent/FR2882261B1/en
Priority claimed from PCT/FR2006/000376 external-priority patent/WO2006087481A1/en
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of IL185401A0 publication Critical patent/IL185401A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL185401A 2005-02-21 2007-08-20 Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes IL185401A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0501861A FR2882261B1 (en) 2005-02-21 2005-02-21 USE OF A PYRAZOLE DERIVATIVE FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE PREVENTION AND TREATMENT OF TYPE 2 DIABETES
FR0504942A FR2882264A1 (en) 2005-02-21 2005-05-12 Use of rimonabant and N-peperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxamide, having cannabinoids receptor antagonistic activity, to treat and prevent type-II diabetes
FR0505228A FR2882265B1 (en) 2005-02-21 2005-05-23 USE OF A PYRAZOLE DERIVATIVE FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE PREVENTION AND TREATMENT OF TYPE 2 DIABETES.
PCT/FR2006/000376 WO2006087481A1 (en) 2005-02-21 2006-02-20 Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes

Publications (1)

Publication Number Publication Date
IL185401A0 true IL185401A0 (en) 2008-08-07

Family

ID=36809538

Family Applications (1)

Application Number Title Priority Date Filing Date
IL185401A IL185401A0 (en) 2005-02-21 2007-08-20 Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes

Country Status (10)

Country Link
JP (1) JP2008530189A (en)
BR (1) BRPI0608183A2 (en)
CR (1) CR9293A (en)
EA (1) EA011618B1 (en)
FR (2) FR2882264A1 (en)
IL (1) IL185401A0 (en)
MA (1) MA29262B1 (en)
MX (1) MX2007009996A (en)
TN (1) TNSN07297A1 (en)
TW (1) TW200640457A (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2789079B3 (en) * 1999-02-01 2001-03-02 Sanofi Synthelabo PYRAZOLECARBOXYLIC ACID DERIVATIVE, ITS PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity

Also Published As

Publication number Publication date
TW200640457A (en) 2006-12-01
MX2007009996A (en) 2007-10-10
FR2882265A1 (en) 2006-08-25
EA011618B1 (en) 2009-04-28
EA200701781A1 (en) 2007-12-28
CR9293A (en) 2007-10-01
JP2008530189A (en) 2008-08-07
FR2882264A1 (en) 2006-08-25
BRPI0608183A2 (en) 2009-11-17
MA29262B1 (en) 2008-02-01
TNSN07297A1 (en) 2008-12-31
FR2882265B1 (en) 2009-02-13

Similar Documents

Publication Publication Date Title
IL195947A (en) Fused cyclic compounds and pharmaceutical compositions comprising them for use in the prevention and treatment of diabetes
IL178822A (en) 4-phenylamino-quinazolin-6-yl-amides, pharmaceutical compositions comprising the same and use thereof in the preparation of medicaments for the treatment of proliferative disorders
IL231576A (en) Adamantyl-acetamide derivatives, pharmaceutical compositions comprising same and use thereof in the manufacture of medicaments
IL188732A (en) Use of ibuprofen and famotidine in the preparation of medicaments
IL183101A (en) Use of tetrahydrocannabivarin in the manufacture of medicaments
IL181524A (en) Heterocyclic compounds, pharmaceutical compositions containing them and their use in the manufacture of medicaments
IL206296A (en) Aminopyrazole derivatives, pharmaceutical compositions comprising them and their use in the manufacture of medicaments for prevention or treatment of diseases
IL194699A (en) Tetrahydropteridines, compositions comprising them and use thereof in the preparation of medicaments
PL1912650T3 (en) Use of flibanserin in the treatment of obesity
IL206080A0 (en) Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases
EP2091540A4 (en) Pyrazolyl derivatives with analgesic activity and therefore useful in the treatment or prophylaxis of pain.
EP2164490A4 (en) Pyrazolyl derivatives with analgesic activity and therefore useful in the treatment or prophylaxis of pain.
GB0523576D0 (en) Drug composition and its use in therapy
ZA201003037B (en) Use of 3, 11b-cis-dihydrotettabenazine in the treatment of multiple sclerosis and autoimmune myelitis
IL194880A (en) Aminothiazole derivatives, their use in the treatment of diseases and pharmaceutical compositions comprising them
IL178903A0 (en) Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
IL195441A0 (en) Use of trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthaleneamine and its formamide in the preparation of medicaments for the treatment of pain disorders
ZA200702421B (en) Iron complex for use in the treatment and/or prevention of nutritional disorders
IL184697A (en) Injectable preparation containing diclofenic, a process for its preparation and use of the preparation in the manufacture of medication for the relief of pain and/or inflammation
EP2005964A4 (en) The medicament for treating hyperphospheremia and preparation thereof
IL201426A0 (en) Drug combination and its use in the treatment of muscle loss
EP1757282A4 (en) The use of kauranes compounds in the manufacture of medicament
PL2193789T3 (en) The application of 3,5-dihydroxytoluene or derivatives thereof in the preparation of medicine and functional food for treating or preventing depression
EP1944039A4 (en) Drug for treating tumor and use thereof in the manufature of medicaments for treating tumor
ZA200707012B (en) Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes